PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

Kim A Papp Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

05/2008	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
05/2008	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
01/2008	Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial.
06/2007	The safety of etanercept for the treatment of plaque psoriasis.
06/2006	The long-term efficacy and safety of new biological therapies for psoriasis.
05/2006	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
04/2006	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
04/2006	Long-term management of plaque psoriasis with continuous efalizumab therapy.
01/2006	Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
01/2006	Evaluation of efalizumab using safe psoriasis control.
12/2005	Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
12/2005	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
03/2005	Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
11/2004	Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator.
10/2004	Etanercept in psoriasis.
01/2004	Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
12/2003	Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
01/2003	Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.
12/2002	A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Articles by Research Topic

Disease

19	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2008 - 12/2002
2	Atopic Dermatitis (Atopic Eczema) 02/2005 - 02/2005
1	Psoriatic Arthritis 03/2007

Drug/Important Bio-Agent (IBA)

13	efalizumab FDA Link 01/2008 - 12/2003
2	Interleukin-12 (IL 12)IBA 05/2008 - 05/2008
2	TNFR-Fc fusion protein (etanercept)FDA Link 06/2007 - 10/2004
2	pimecrolimus (Elidel)FDA Link 02/2005 - 02/2005
1	AntibodiesIBA 02/2005
1	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 01/2003
1	calcipotriene (calcipotriol)FDA LinkGeneric 01/2003
1	alefacept (Amevive)FDA Link 12/2002

Therapy/Procedure

1	Biological Therapy 06/2006
1	Retreatment 04/2006